Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Spanish move to address latex allergy rates

This article was originally published in Clinica

Executive Summary

High rates of latex allergy continue to afflict Spanish healthcare workers, prompting national allergology and clinical immunology association SEAIC to establish a committee to address the issue. An estimated 3-10% of all healthcare workers are thought to have an allergic reaction upon contact with latex. The figure is far higher among certain patient groups, however: up to 50% of people who have been operated more than once or who have spina bifida, claims the Madrid-based group. "In recent years, the issue of latex allergy has become a healthcare and social problem of the first order," said the committee's co-ordinator, Dr Nieves Cabanes. In addition to acting as a source of information and support, the committee is to compile detailed data of the problem, to establish its true extent and be in a better position to adopt preventive measures, said SEAIC.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT047576

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel